New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 5, 2012
07:07 EDTENDPEndo Health sees FY12 CapEx $120M
News For ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
07:21 EDTENDPEndo shares have attractive long-term setup, says JPMorgan
JPMorgan believes the acquisition of Par builds out Endo's generics business. The firm believes the long-term setup for Endo is attractive and raised its price target for shares to $110 from $105. It reiterates an Overweight rating on the name.
May 19, 2015
10:14 EDTENDPHigh option volume stocks
Subscribe for More Information
07:39 EDTENDPEndo presents data on Xiaflex treatment for PD
Endo Pharmaceuticals, a subsidiary of Endo International, supports efforts to bring the medical community the first ever treatment guidelines for Peyronie's Disease, or PD, a condition in which collagen plaque, or scar tissue, develops on the shaft of the penis, and may harden and reduce flexibility. The company also announced that it has presented encore data at a key medical meeting evaluating the efficacy of XIAFLEX treatment for PD as well as the impact of PD on erectile dysfunction and female partners.
May 18, 2015
16:21 EDTENDPOn The Fly: Top stock stories for Monday
Stocks on Wall Street advanced in Monday trading, sending the Dow Jones Industrial Average and the S&P 500 to new all-time closing highs. The early part of the day saw the market move in a narrow range, but by early afternoon the market punched through its upper range and moved to session highs. The market drifted throughout the afternoon as the news flow was quiet and the trading volume remained light. ECONOMIC EVENTS: In the U.S., the National Association of Home Builders’ confidence index fell 2 points to a reading of 54 in May, missing expectations for a 1 point increase to a reading of 57. COMPANY NEWS: Shares of Apple (AAPL) advanced $1.47, or 1.14%, to $130.24 after noted investor Carl Icahn stated in an open letter to the company's CEO that he thinks other investors, analysts and the news media continue to misunderstand Apple and that its stock is "worth $240 today." Icahn urged Apple CEO Tim Cook to take advantage by launching a "much larger buyback" of the iPhone maker's shares. Separately, FBR Capital analysts Daniel Ives and James Moore wrote this morning in a note to investors that the Street is still underestimating Apple's growth outlook in China. The analysts believe that Apple's China revenue will exceed its revenue from the Americas in fiscal 2017... Endo International (ENDP) slid $4.53, or 5.31%, to $80.82 after the company agreed to pay $8B for privately held Par Pharmaceutical, which will roughly double Endo’s generics revenue and place its generics business among the top five as measured by U.S. sales. MAJOR MOVERS: Among the notable gainers was Ann Inc. (ANN), which surged $7.69, or 19.87%, to $46.40 after agreeing to be acquired by Ascena Retail Group (ASNA) for about $2.15B in cash and stock. Ascena, which agreed to pay $37.34 in cash and 0.68 of a share of its own common stock in exchange for each share of the parent of the Ann Taylor brand, slipped 14c, or 0.99%, to $14.07 after announcing the deal. Also higher was Achillion (ACHN), which rose $1.41, or 14.79%, to $10.98 after the company cancelled its presentation at the UBS Global Healthcare Conference. Conference cancellations often generate speculation as to whether a company is engaged in merger or acquisition talks. Among the noteworthy losers was Eleven Biotherapeutics (EBIO), which dropped $8.29, or 69.26%, to $3.68 after announcing the company’s Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease did not meet either of its two co-primary endpoints. Also lower were shares of Weibo (WB), which fell 87c, or 5.24%, to $15.73 after the shares were downgraded to Hold from Buy at Summit Research. INDEXES: The Dow rose 26.32, or 0.14%, to 18,298.88, the Nasdaq gained 30.15, or 0.6%, to 5,078.44, and the S&P 500 added 6.47, or 0.3%, to 2,129.20.
14:42 EDTENDPAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
09:20 EDTENDPEndo CEO says will be looking for deals on lower end of $300M-$1B range
Endo will be looking for deals similar to its Aspen transaction, the company's CEO added.
09:09 EDTENDPEndo says 'pretty large' disparity in FY16 interest expense view vs. consensus
Endo said it will not give FY16 guidance at this point but noted that there appears to be a "pretty large" disparity between the company's interest expense view for the fiscal year compared to what appears to be factored into the consensus FY16 forecast. Comments from Endo's call discussing its deal to acquire Par Pharmaceutical.
08:27 EDTENDPEndo says Par financing structure provides flexibility for future M&A
Endo expects adjusted diluted Par EPS to grow faster than revenues, according to slides for the Par Pharmaceutical acquisition presentation. Endo anticipates returns well in excess of its cost of capital, which should enable de-levering to a projected 3-4x net debt to EBITDA in 12-18 months. Endo said the financing structure of the Par deal provides flexibility for future M&A. Endo says consolidation and maturation of competitors have stabilized the generic pharmaceuticals pricing environment and that adding Par creates a top five generics player. Endo said it will have pro forma filed ANDAs of 165 and pro forma programs in development of 152 after adding Par.
06:36 EDTENDPEndo sees PAR transaction accretive to adjusted EPS in first 12 months
Subscribe for More Information
06:34 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Endo and Par Pharmaceutical announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05B, including assumption of Par debt. The combination is expected to help drive long-term double-digit revenue growth for Endo. The transaction has been unanimously approved by the boards of Endo and Par, and is supported by the management teams of both companies. There are no further shareholder approvals required. The purchase price will consist of approximately 18M shares, $1.55B of value based on the 10-day volume weighted average share price of Endo ending on May 15, of Endo equity and $6.50B cash consideration to Par shareholders. Endo has secured fully committed financing from Deutsche Bank and Barclays to fund the cash consideration. Endo expects to implement a permanent capital structure to finance the transaction prior to the close that would include a combination of cash, debt and an equity offering. The transaction is expected to close in the second half of 2015 and is subject to regulatory approval in the U.S. and certain other jurisdictions, as well as other customary closing conditions.
06:33 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
06:31 EDTENDPEndo to acquire Par Pharmaceutical in transaction valued at $8.05B
Subscribe for More Information
May 15, 2015
17:40 EDTENDPEndo announces FDA approval of label update for XIAFLEX
Subscribe for More Information
17:08 EDTENDPSoros Fund gives quarterly update on stakes
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use